Patents Assigned to Kaleidos Pharma, Inc.
  • Loop peptide and TGFalpha for stimulating stem cell proliferation and migration
    Publication number: 20060105957
    Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF?, was discovered as having TGF? biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF? polypeptide. There is further disclosed that TGF? and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.
    Type: Application
    Filed: July 16, 2004
    Publication date: May 18, 2006
    Applicant: Kaleidos Pharma, Inc.
    Inventors: Daniel Twardzik, Stefan Paskell, Thomas Felker
  • TGF-&agr; polypeptides, functional fragments and methods of use therefor
    Patent number: 6815418
    Abstract: Disclosed are TGF-&agr; polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 9, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Loop peptide and TGF&agr; for stimulating stem cell proliferation and migration
    Patent number: 6764683
    Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF&agr;, was discovered as having TGF&agr; biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF&agr; polypeptide. There is further disclosed that TGF&agr; and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: July 20, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
  • TGF-&agr; polypeptides, functional fragments and methods of use therefor
    Patent number: 6677307
    Abstract: Disclosed are TGF-60 mimetics that PEGylated TGF-&agr; polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: January 13, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell, John M. Reno